Recursion (RXRX) lost more than 4% in the early premarket trading on Thursday after a $200M equity offering from the AI-driven drug discovery firm overshadowed a decision by Sanofi (SNY) to select its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...

Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...

Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...

Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross proceeds of about $200 million.

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...

Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Grade 3 ...

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...

Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, ...